Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months ahead of plan; topline data expected Q1 2027Drug candidate, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results